A Randomized Study of Quantiferon CMV-directed Versus Fixed-duration Valganciclovir Prophylaxis to Reduce Late CMV After Lung Transplantation
Sign Up to like & getrecommendations! Published in 2019 at "Transplantation Direct"
DOI: 10.1097/tp.0000000000002454
Abstract: Background. We provide the results of the first interventional study of cytomegalovirus (CMV)-specific immune monitoring to direct the length of antiviral prophylaxis in lung transplantation (LTx). Methods. Patients (n = 118) at risk of CMV… read more here.
Keywords: lung; valganciclovir prophylaxis; late cmv; cmv ... See more keywords
Valganciclovir prophylaxis extension from 3 to 6 months in high‐risk pancreas‐transplant recipients does not impact incidence of cytomegalovirus infection at 12 months
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Transplantation"
DOI: 10.1111/ctr.14379
Abstract: Incidence and impact of CMV infection in pancreas‐transplant recipients (PTRs) in the valganciclovir prophylaxis era has not been completely elucidated. read more here.
Keywords: incidence; valganciclovir prophylaxis; prophylaxis extension; infection ... See more keywords
Clinical outcomes of valganciclovir prophylaxis in high‐risk (D+/R−) renal transplant recipients experiencing delayed graft function
Sign Up to like & getrecommendations! Published in 2019 at "Transplant Infectious Disease"
DOI: 10.1111/tid.13125
Abstract: Cytomegalovirus (CMV) outcomes with valganciclovir prophylaxis in renal transplant recipients experiencing delayed graft function (DGF) are unclear. read more here.
Keywords: valganciclovir prophylaxis; recipients experiencing; transplant; outcomes valganciclovir ... See more keywords